Insys Therapeutics Inc (INSY) 27.63 $INSY
Insys Therapeutics Reports First Quarter 2014 Results
Marketwire - 41 mins ago
Insys Therapeutics, Inc. (NASDAQ: INSY), today announced its financial results for the three-month period ended March 31, 2014. First quarter 2014 highlights include:
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims against INSYS Therapeutics, Inc. --- INSY
Business Wire - Mon May 12, 9:38PM CDT
The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against INSYS Therapeutics, Inc. (Nasdaq:INSY) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of INSYS Therapeutics, Inc. - INSY
PR Newswire - Mon May 12, 3:49PM CDT
Pomerantz LLP is investigating claims on behalf of investors of INSYS Therapeutics, Inc. ("INSYS" or the "Company"
(NASDAQ: INSY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.
Insys Therapeutics Issues Clarifying Statement
Marketwire - Mon May 12, 2:30PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today issued a clarifying statement regarding its Subsys(R) (fentanyl sublingual spray) product.
Why Insys Theraputics Inc. Shares Are Imploding
Alex Planes, The Motley Fool - Motley Fool - Mon May 12, 2:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insys Therapeutics have fallen 14%...
INSYS Investigation Initiated by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates INSYS Therapeutics, Inc. Following Disclosure of Doctor Charged with Fraud and Insider Sales
Business Wire - Mon May 12, 1:17PM CDT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF" , announces that KSF has commenced an investigation into INSYS Therapeutics, Inc. (Nasdaq: INSY).
Nasdaq stocks posting largest percentage decreases
AP - Mon May 12, 12:21PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why Insys Therapeutics (INSY) Stock Is Plunging Today
at The Street - Mon May 12, 11:41AM CDT
Insys Therapeutics (INSY) continued to plunge Monday after Friday's report from a Michigan local news site that a doctor had allegedly committed fraud in prescribing the company's drug Subsys.
Allscripts Healthcare Solutions Misses, Earnings Continue to Dip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:50AM CDT
On a reported basis, Allscripts Healthcare Solutions (MDRX) incurred a broader loss of $20.7 million or 12 cents per share compared with $11.6 million or 7 cents in the first quarter of 2013
athenahealth Crumbles on Einhorn's Short Call - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:20PM CDT
Shares of athenahealth (ATHN) sunk nearly 15% to date after Einhorn's description of it as a "bubble stock."
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
CareFusion's Flat Earnings Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 9:48AM CDT
CareFusion (CFN) upgraded its revenues and earnings guidance for fiscal 2014.
Insys Therapeutics to Present at 2014 UBS Global Healthcare Conference
Marketwire - Wed May 07, 6:04AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the company will present at the 2014 UBS Global Healthcare Conference on May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City.
Insys to Advance Development of Pharmaceutical Cannabidiol (CBD) to Treat Epilepsy in Children and Adults
Marketwire - Wed May 07, 5:10AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) announced today plans to advance development of its pharmaceutical Cannabidiol (CBD), a synthetically produced and over 99% pure form of cannabidiol, to treat epilepsy in children and adults. Insys has engaged a large international Clinical Research Organization to provide development and regulatory services and has hired Mark Davis as Senior Clinical Director to oversee this program.
Epilepsy Foundation Announces Stellar Line Up of Presenters and Topics for Epilepsy Pipeline Conference in San Francisco June 5-7, 2014
Marketwire - Mon May 05, 8:44AM CDT
The Epilepsy Foundation announced today that the 4th Biennial Epilepsy Pipeline Conference 2014, an initiative of the Epilepsy Therapy Project, will feature a stellar line up of therapeutic and medical device developers, clinical investigators and industry leaders presenting the latest epilepsy therapies in development. The conference will highlight the most pressing issues faced by the epilepsy community today including the evaluation of medical marijuana; how to accelerate epilepsy research innovation to the next stage; and the urgent unmet need for new therapies for the millions of people with epilepsy who are not receiving adequate seizure control. This year's conference will also feature the annual "Shark Tank " competition where new ideas arising from researchers and entrepreneurs are invited to compete for funding that will advance their inventive product concepts with the promise of improving the lives of people with epilepsy. The Epilepsy Pipeline Conference will be held on June 5-7, 2014, at the Hyatt Regency San Francisco.
Recurrent Malignant Glioma linical Trials Review - H1 2014 Edition
M2 - Thu May 01, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2n5m9j/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Insys Therapeutics, Inc. - Merck & Co., Inc. - Eisai Co., Ltd. - TransMolecular, Inc. - Eli Lilly and Company - to-BBB technologies BV - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Direct Therapeutics, Inc. - Amgen Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - Northwestern University - UCLA's Jonsson Comprehensive Cancer Center - Sidney Kimmel Comprehensive Cancer Center - University of Colorado - Wake Forest University For more information visit http://www.researchandmarkets.com/research/2n5m9j/recurrent
Global Pheochromocytoma Global Clinical Trials Review 2014 - Espy the Top 15 Companies/Institutions
M2 - Wed Apr 30, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvv7qm/pheochromocytoma) has announced the addition of the "Pheochromocytoma Global Clinical Trials Review, H1, 2014" report to their offering. Pheochromocytoma Global Clinical Trials Review, H1, 2014" provides data on the Pheochromocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pheochromocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pheochromocytoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Progenics Pharmaceuticals, Inc. - Nektar Therapeutics - Jubilant Life Sciences Limited - Insys Therapeutics, Inc. - GE Healthcare - National Cancer Institute - University of California, San Francisco - Seoul National University Hospital - Assistance Publique Hopitaux De Marseille - Cincinnati Children's Hospital Medical Center - European Organization for Research and Treatment of Cancer - University Medical Center Groningen - University of Southern California - Rouen University Hospital - University Hospital, Angers For more information visit http://www.researchandmarkets.com/research/mv...romocytoma
Insys Therapeutics to Report First Quarter 2014 Results
Marketwire - Tue Apr 29, 3:31PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the first quarter 2014 on Tuesday, May 13, 2014, before the U.S. financial markets open.
Reported and Upcoming Financial Results, Upcoming Conference Participations, and US FDA Approval - Analyst Notes on AMAG, Insys Therapeutics, Cayman, Lannett and Magellan Health Services
PR Newswire - Tue Apr 29, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Insys Therapeutics, Inc. (NASDAQ: INSY), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Lannett Company, Inc. (NYSE: LCI) and Magellan Health Services Inc. (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1741-100free.
Insys Therapeutics Reports First Quarter 2014 Results
Marketwire - 41 mins ago
Insys Therapeutics, Inc. (NASDAQ: INSY), today announced its financial results for the three-month period ended March 31, 2014. First quarter 2014 highlights include:
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Fraud Claims against INSYS Therapeutics, Inc. --- INSY
Business Wire - Mon May 12, 9:38PM CDT
The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against INSYS Therapeutics, Inc. (Nasdaq:INSY) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of INSYS Therapeutics, Inc. - INSY
PR Newswire - Mon May 12, 3:49PM CDT
Pomerantz LLP is investigating claims on behalf of investors of INSYS Therapeutics, Inc. ("INSYS" or the "Company"
(NASDAQ: INSY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. Insys Therapeutics Issues Clarifying Statement
Marketwire - Mon May 12, 2:30PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today issued a clarifying statement regarding its Subsys(R) (fentanyl sublingual spray) product.
Why Insys Theraputics Inc. Shares Are Imploding
Alex Planes, The Motley Fool - Motley Fool - Mon May 12, 2:00PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Insys Therapeutics have fallen 14%...
INSYS Investigation Initiated by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates INSYS Therapeutics, Inc. Following Disclosure of Doctor Charged with Fraud and Insider Sales
Business Wire - Mon May 12, 1:17PM CDT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"
, announces that KSF has commenced an investigation into INSYS Therapeutics, Inc. (Nasdaq: INSY). Nasdaq stocks posting largest percentage decreases
AP - Mon May 12, 12:21PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Why Insys Therapeutics (INSY) Stock Is Plunging Today
at The Street - Mon May 12, 11:41AM CDT
Insys Therapeutics (INSY) continued to plunge Monday after Friday's report from a Michigan local news site that a doctor had allegedly committed fraud in prescribing the company's drug Subsys.
Allscripts Healthcare Solutions Misses, Earnings Continue to Dip - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 8:50AM CDT
On a reported basis, Allscripts Healthcare Solutions (MDRX) incurred a broader loss of $20.7 million or 12 cents per share compared with $11.6 million or 7 cents in the first quarter of 2013
athenahealth Crumbles on Einhorn's Short Call - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu May 08, 3:20PM CDT
Shares of athenahealth (ATHN) sunk nearly 15% to date after Einhorn's description of it as a "bubble stock."
Chronic Pain - Pipeline Review, H1 2014: 61 Companies and 125 Drugs Profiled
M2 - Wed May 07, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/xqd2j5/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AbbVie Inc. - Acadia Pharmaceuticals Inc. - Adynxx, Inc. - Afferent Pharmaceuticals, Inc. - Akron Molecules GmbH - Allergan, Inc. - AstraZeneca PLC - Benitec Biopharma Limited - Bionomics Limited - Cara Therapeutics, Inc. - ChironWells GmbH - Chromocell Corporation - CoLucid Pharmaceuticals, Inc. - Collegium Pharmaceutical, Inc. - Concert Pharmaceuticals, Inc. - Convergence Pharmaceuticals Ltd. - Creabilis SA - DURECT Corporation - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - Debiopharm International S.A. - Eli Lilly and Company - Elite Pharmaceuticals, Inc. - Endo Pharmaceuticals Inc. - Glenmark Pharmaceuticals Ltd. - GlobalAcorn - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immupharma Plc - Insys Therapeutics, Inc. Drug Profiles: - oxycodone ER - (oxycodone hydrochloride naloxone hydrochloride) - fentanyl citrate - celecoxib - hydrocodone bitartrate ER - (oxycodone naltrexone) - tapentadol hydrochloride - duloxetine hydrochloride DR - oxycodone hydrochloride ER - buprenorphine hydrochloride - tramadol hydrochloride SR - hydrocodone bitartrate - tapentadol hydrochloride ER - (oxycodone hydrochloride naltrexone hydrochloride) Extended Release - PRC-062 - sufentanil - tapentadol hydrochloride - (morphine oxycodone) CR - AGN-XX/YY - cebranopadol - onabotulinumtoxinA - NKTR-181 - sufentanil - SAR-292833 - dexmedetomidine hydrochloride - DS-5565 - CNV-2197944 - dexmedetomidine - (celecoxib tramadol hydrochloride) For more information visit http://www.researchandmarkets.com/research/xq...ronic_pain
CareFusion's Flat Earnings Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 9:48AM CDT
CareFusion (CFN) upgraded its revenues and earnings guidance for fiscal 2014.
Insys Therapeutics to Present at 2014 UBS Global Healthcare Conference
Marketwire - Wed May 07, 6:04AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the company will present at the 2014 UBS Global Healthcare Conference on May 19-21, 2014 at the Sheraton New York Times Square Hotel in New York City.
Insys to Advance Development of Pharmaceutical Cannabidiol (CBD) to Treat Epilepsy in Children and Adults
Marketwire - Wed May 07, 5:10AM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) announced today plans to advance development of its pharmaceutical Cannabidiol (CBD), a synthetically produced and over 99% pure form of cannabidiol, to treat epilepsy in children and adults. Insys has engaged a large international Clinical Research Organization to provide development and regulatory services and has hired Mark Davis as Senior Clinical Director to oversee this program.
Epilepsy Foundation Announces Stellar Line Up of Presenters and Topics for Epilepsy Pipeline Conference in San Francisco June 5-7, 2014
Marketwire - Mon May 05, 8:44AM CDT
The Epilepsy Foundation announced today that the 4th Biennial Epilepsy Pipeline Conference 2014, an initiative of the Epilepsy Therapy Project, will feature a stellar line up of therapeutic and medical device developers, clinical investigators and industry leaders presenting the latest epilepsy therapies in development. The conference will highlight the most pressing issues faced by the epilepsy community today including the evaluation of medical marijuana; how to accelerate epilepsy research innovation to the next stage; and the urgent unmet need for new therapies for the millions of people with epilepsy who are not receiving adequate seizure control. This year's conference will also feature the annual "Shark Tank " competition where new ideas arising from researchers and entrepreneurs are invited to compete for funding that will advance their inventive product concepts with the promise of improving the lives of people with epilepsy. The Epilepsy Pipeline Conference will be held on June 5-7, 2014, at the Hyatt Regency San Francisco.
Recurrent Malignant Glioma linical Trials Review - H1 2014 Edition
M2 - Thu May 01, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2n5m9j/recurrent) has announced the addition of the "Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Recurrent Malignant Glioma Global Clinical Trials Review, H1, 2014" provides data on the Recurrent Malignant Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Recurrent Malignant Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Recurrent Malignant Glioma. Espy the commercial landscape of the major Universities / Institutes / Hospitals & Companies - Insys Therapeutics, Inc. - Merck & Co., Inc. - Eisai Co., Ltd. - TransMolecular, Inc. - Eli Lilly and Company - to-BBB technologies BV - Tactical Therapeutics, Inc - Shandong Lanjin Pharmaceuticals Co. Ltd - Direct Therapeutics, Inc. - Amgen Inc. - National Cancer Institute - Duke University - Memorial Sloan Kettering Cancer Center - North American Brain Tumor Consortium - The University of Texas M. D. Anderson Cancer Center - Northwestern University - UCLA's Jonsson Comprehensive Cancer Center - Sidney Kimmel Comprehensive Cancer Center - University of Colorado - Wake Forest University For more information visit http://www.researchandmarkets.com/research/2n5m9j/recurrent
Global Pheochromocytoma Global Clinical Trials Review 2014 - Espy the Top 15 Companies/Institutions
M2 - Wed Apr 30, 9:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvv7qm/pheochromocytoma) has announced the addition of the "Pheochromocytoma Global Clinical Trials Review, H1, 2014" report to their offering. Pheochromocytoma Global Clinical Trials Review, H1, 2014" provides data on the Pheochromocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pheochromocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pheochromocytoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Progenics Pharmaceuticals, Inc. - Nektar Therapeutics - Jubilant Life Sciences Limited - Insys Therapeutics, Inc. - GE Healthcare - National Cancer Institute - University of California, San Francisco - Seoul National University Hospital - Assistance Publique Hopitaux De Marseille - Cincinnati Children's Hospital Medical Center - European Organization for Research and Treatment of Cancer - University Medical Center Groningen - University of Southern California - Rouen University Hospital - University Hospital, Angers For more information visit http://www.researchandmarkets.com/research/mv...romocytoma
Insys Therapeutics to Report First Quarter 2014 Results
Marketwire - Tue Apr 29, 3:31PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) today announced that the Company will release its financial results for the first quarter 2014 on Tuesday, May 13, 2014, before the U.S. financial markets open.
Reported and Upcoming Financial Results, Upcoming Conference Participations, and US FDA Approval - Analyst Notes on AMAG, Insys Therapeutics, Cayman, Lannett and Magellan Health Services
PR Newswire - Tue Apr 29, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG), Insys Therapeutics, Inc. (NASDAQ: INSY), WuXi PharmaTech (Cayman) Inc. (NYSE: WX), Lannett Company, Inc. (NYSE: LCI) and Magellan Health Services Inc. (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1741-100free.
